In silico study: combination of α-mangostin and chitosan conjugated with trastuzumab against human epidermal growth factor receptor 2
Polymers, 2022•mdpi.com
Breast cancer is a type of cancer with the highest prevalence worldwide. Almost 10–30% of
breast cancer cases are diagnosed as positive for HER2 (human epidermal growth factor
receptor 2). The currently available treatment methods still exhibit many shortcomings such
as a high incidence of side effects and treatment failure due to resistance. This in silico study
aims to simulate α-mangostin and chitosan combination conjugated to trastuzumab
formulation against HER2 as an effort to improve breast cancer patient therapy. This …
breast cancer cases are diagnosed as positive for HER2 (human epidermal growth factor
receptor 2). The currently available treatment methods still exhibit many shortcomings such
as a high incidence of side effects and treatment failure due to resistance. This in silico study
aims to simulate α-mangostin and chitosan combination conjugated to trastuzumab
formulation against HER2 as an effort to improve breast cancer patient therapy. This …
Breast cancer is a type of cancer with the highest prevalence worldwide. Almost 10–30% of breast cancer cases are diagnosed as positive for HER2 (human epidermal growth factor receptor 2). The currently available treatment methods still exhibit many shortcomings such as a high incidence of side effects and treatment failure due to resistance. This in silico study aims to simulate α-mangostin and chitosan combination conjugated to trastuzumab formulation against HER2 as an effort to improve breast cancer patient therapy. This molecular docking simulation was done through using PatchDock Server. The materials used including the two-dimensional structure of α-mangostin, chitosan, and sodium tripolyphosphate from the PubChem database; trastuzumab FASTA sequence from the DrugBank database; and HER2 structure obtained from a crystal complex with PDB ID: 1N8Z. The results indicated that the particle of α-mangostin and chitosan combinations interacted mostly with the crystallizable fragment (Fc region) of trastuzumab in the conjugation process. The conjugation of trastuzumab to the particle of a combination of α-mangostin and chitosan resulted in the greatest increase in the binding score of the smallest-sized particles (50 Å) with an increase in the score of 3828 and also gave the most similar mode of interaction with trastuzumab. However, the conjugation of trastuzumab eliminated the similarity of the mode of interaction and increased the value of atomic contact energy. Thus, a cominbation of α-mangostin and chitosan conjugated to a trastuzumab formulation was predicted can increase the effectiveness of breast cancer therapy at a relatively small particle size but with the consequence of decreasing atomic contact energy.
![](/scholar/images/qa_favicons/mdpi.com.png)
以上显示的是最相近的搜索结果。 查看全部搜索结果